AEOL 10150 treatment shown to improve survival from nitrogen mustard

Aeolus Pharmaceuticals, Inc., announced on Tuesday the results of its completed studies for AEOL 10150, which showed significant skin protection against nitrogen mustard gas.

"Treatment with AEOL 10150 by injection and topically of animals exposed to nitrogen mustard gas resulted in 100 percent survival at 120 hours after exposure compared to 38 percent survival for untreated animals," Brian Day, professor and vice chair of research at the Department of Medicine at National Jewish Health and Aeoluschief science officer said. "These results build on the efficacy we have seen with AEOL 10150 against sulfur mustard gas, chlorine gas and phosgene gas, and demonstrate the compounds potential as a broad spectrum countermeasure for chemical threats."

AEOL 10150 works as a catalytic antioxidant designed to neutralize reactive oxygen and nitrogen elements. This results in the reduction of tissue damage-signaling cascades resulting from radiation exposure, among other benefits.

There is currently no treatment for nitrogen gas exposure, which is why the National Institute of Health CounterACT program sponsored the research grant.

The data was presented at the 6th Annual NIH CounterACT Network Research Symposium. Mustard gas has been stockpiled by countries for military use since World War II. Exposure to the gas causes blistering of the skin and death.

Organizations in this Story

Aeolus Pharmaceuticals

Want to get notified whenever we write about Aeolus Pharmaceuticals ?
Next time we write about Aeolus Pharmaceuticals, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.